Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males

Trial Profile

Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs PXS-5338K (Primary)
  • Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
  • Focus Adverse reactions
  • Sponsors Pharmaxis
  • Most Recent Events

    • 11 Oct 2018 Results of this trial for first Lysyl Oxidase Like 2 (LOXL2) inhibitor (PXS-5338K) presented in an Arix Bioscience media release.
    • 24 Sep 2018 The actual date of last participant enrollment is 5/6/2018
    • 24 Sep 2018 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top